PortfoliosLab logo
RNA vs. STRO
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between RNA and STRO is 0.30, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Performance

RNA vs. STRO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Avidity Biosciences, Inc. (RNA) and Sutro Biopharma, Inc. (STRO). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

RNA:

0.20

STRO:

-0.66

Sortino Ratio

RNA:

0.91

STRO:

-1.05

Omega Ratio

RNA:

1.11

STRO:

0.87

Calmar Ratio

RNA:

0.33

STRO:

-0.80

Martin Ratio

RNA:

0.59

STRO:

-1.46

Ulcer Index

RNA:

29.76%

STRO:

53.69%

Daily Std Dev

RNA:

72.87%

STRO:

120.00%

Max Drawdown

RNA:

-86.45%

STRO:

-98.10%

Current Drawdown

RNA:

-40.99%

STRO:

-96.74%

Fundamentals

Market Cap

RNA:

$3.73B

STRO:

$76.02M

EPS

RNA:

-$3.00

STRO:

-$2.91

PS Ratio

RNA:

418.25

STRO:

1.14

PB Ratio

RNA:

2.81

STRO:

2.11

Total Revenue (TTM)

RNA:

$8.93M

STRO:

$66.43M

Gross Profit (TTM)

RNA:

$5.93M

STRO:

$2.55M

EBITDA (TTM)

RNA:

-$431.82M

STRO:

-$200.97M

Returns By Period

In the year-to-date period, RNA achieves a 6.53% return, which is significantly higher than STRO's -51.21% return.


RNA

YTD

6.53%

1M

-5.23%

6M

-28.00%

1Y

15.34%

3Y*

30.53%

5Y*

N/A

10Y*

N/A

STRO

YTD

-51.21%

1M

-16.10%

6M

-66.12%

1Y

-78.75%

3Y*

-40.91%

5Y*

-38.26%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Avidity Biosciences, Inc.

Sutro Biopharma, Inc.

Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

RNA vs. STRO — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RNA
The Risk-Adjusted Performance Rank of RNA is 6161
Overall Rank
The Sharpe Ratio Rank of RNA is 5959
Sharpe Ratio Rank
The Sortino Ratio Rank of RNA is 6363
Sortino Ratio Rank
The Omega Ratio Rank of RNA is 6060
Omega Ratio Rank
The Calmar Ratio Rank of RNA is 6666
Calmar Ratio Rank
The Martin Ratio Rank of RNA is 5858
Martin Ratio Rank

STRO
The Risk-Adjusted Performance Rank of STRO is 1010
Overall Rank
The Sharpe Ratio Rank of STRO is 1414
Sharpe Ratio Rank
The Sortino Ratio Rank of STRO is 1111
Sortino Ratio Rank
The Omega Ratio Rank of STRO is 1313
Omega Ratio Rank
The Calmar Ratio Rank of STRO is 55
Calmar Ratio Rank
The Martin Ratio Rank of STRO is 77
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

RNA vs. STRO - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Avidity Biosciences, Inc. (RNA) and Sutro Biopharma, Inc. (STRO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current RNA Sharpe Ratio is 0.20, which is higher than the STRO Sharpe Ratio of -0.66. The chart below compares the historical Sharpe Ratios of RNA and STRO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

RNA vs. STRO - Dividend Comparison

Neither RNA nor STRO has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

RNA vs. STRO - Drawdown Comparison

The maximum RNA drawdown since its inception was -86.45%, smaller than the maximum STRO drawdown of -98.10%. Use the drawdown chart below to compare losses from any high point for RNA and STRO.


Loading data...

Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

RNA vs. STRO - Volatility Comparison

The current volatility for Avidity Biosciences, Inc. (RNA) is 26.12%, while Sutro Biopharma, Inc. (STRO) has a volatility of 30.54%. This indicates that RNA experiences smaller price fluctuations and is considered to be less risky than STRO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading data...

Financials

RNA vs. STRO - Financials Comparison

This section allows you to compare key financial metrics between Avidity Biosciences, Inc. and Sutro Biopharma, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00M100.00M120.00M20212022202320242025
1.57M
17.40M
(RNA) Total Revenue
(STRO) Total Revenue
Values in USD except per share items